NOW Is the Time for Hepatitis C Virus Elimination
Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.
An Activist’s Guide to Shorter Treatment for Drug-Resistant Tuberculosis
An updated, version of this publication was released in 2025. In 2022, the World Health Organization (WHO) updated its guidelines for treating drug-resistant tuberculosis (DR-TB), recommending a six-month cure. This guide lays out what activists need to know about the…
ACTIVISM DELIVERS UNPRECEDENTED VICTORIES IN TB TESTING AND TREATMENT ACCESS
Three recent announcements of tuberculosis (TB) medicine and diagnostics price reductions access will enable millions more people to receive TB preventive therapy, and to be tested and treated for TB. Announced alongside the United Nations General Assembly High-Level Meeting on Tuberculosis (TB) in September, these victories across the cascade of TB care were the result of years of targeted, spirited, and informed mobilization from the TB community.
Beyond Intellectual Property: Why Is Generic Treatment for HCV Still So Hard to Get
By Joelle Dountio Ofimboudem and Sara Helena Gaspar Background Intellectual property is a major barrier to access to medicines worldwide because it creates corporate monopolies that restrict supply, keep prices high, and prevent people from accessing innovative health products. However,…
Misinformation and Vaccine Preparedness: The Case for Digital Advocacy
By Erin McConnell A special thanks to Abraham Johnson, for contributing to an earlier draft of this piece Hesitancy around immunization has such deep historical roots that it predates the first vaccine. Before the term “anti-vaccine” was coined in the…
How Rising Anti-LGBTQ Sentiment Harms Public Health
By Kendall Martinez-Wright, Elizabeth Lovinger, and De’Ashia Lee Many people recognize advances the LGBTQ+ community has made in the United States and other countries, including the freedom to marry their partners, sexual orientation and gender identity protections, and the fact…
Are We There Yet? TB Preventive Treatment Beyond TB/HIV Integration
By Lynette Mabote-Eyde and Mike Frick Too often, major scientific advancements against tuberculosis (TB) get lost on the long and winding road of policy translation into practice. TB preventive treatment (TPT) has faced decades of dislocation between progressive global World…
TAGline October 2023
We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.
TAG Reacts to J&J Commitment to Not Enforce Patents on Bedaquiline
TAG is thrilled by this weekend’s announcement that following years of activist pressure, Johnson & Johnson (J&J) has finally publicly committed to not enforcing its spurious secondary patents on bedaquiline in the treatment of drug-resistant tuberculosis (DR-TB) in 134 low- and middle-income countries.
TAG Remarks Submitted to United Nation High-Level Meetings (UN HLMs), September 2023
TAG prepared these remarks to deliver at United Nations High-Level Meetings (UN HLMs) on tuberculosis (TB), universal health coverage (UHC), and pandemic prevention, preparedness, and response (PPR). While we welcome public reaffirmation of commitments to end TB, we urge member…